BofA cuts MakeMyTrip stock price target on higher expenses

BofA Securities reduced its price target for MakeMyTrip (MMYT) to $55 from $60, citing higher expenses. The stock is down 55% over the past year. MMYT reported 10.5% revenue growth, beating estimates, but net income missed due to higher costs. Adjusted EBIT margins were 1.7%, down 10 basis points year-over-year. The company maintains a strong gross profit margin of 59%.

Original reporting
Published Oct 27, 2026, 8:52 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 27, 2026, 8:58 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$MMYT
Bearish
high confidence
Mentioned
$MMYT
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$MMYTBearishMed
01

Why it matters

The analyst downgrade adds a fresh negative catalyst, likely prompting short‑term selling pressure.

02

Market read

The price‑target cut is a primary piece of news for MMYT, offering a concrete decision point for traders.

03

What to watch

Potential upside from non‑air segments and AI‑driven efficiency gains could offset short‑term revenue miss.

Relevance 7/10Novelty 8/10Timing: pre-market today

Background

MakeMyTrip reported Q2 results with revenue below estimates and a modest EPS beat, while BofA adjusted its target lower.

Company-level read

Ticker impact

$MMYTBearishHigh confidence
Context

BofA Securities lowered its price target on MakeMyTrip to $55 from $60 and reported Q2 earnings miss on revenue, providing fresh analyst guidance.

Expected impact

likely downside as the market prices in the lower target and revenue miss

Evidence & confidence

The target reduction is a new, material change from a major broker and follows a revenue shortfall, both of which typically drive the stock lower.

Market effects

Travel and online booking sector may see broader scrutiny as analysts reassess growth prospects.

India‑focused travel platforms could face similar valuation pressure.

Limited to travel‑tech stocks; no broad market effect.

Counterpoint

Some investors may view the target cut as an overreaction given strong cash position and AI initiatives.

Key entities

  • MakeMyTrip

    Indian online travel booking platform.

  • BofA Securities

    Bank of America research unit providing the price target revision.

Related articles

HighAI 8/10

MakeMyTrip India Subsidiary Gets Sebi Nod for IPO

MakeMyTrip's India subsidiary, MMT India, received Sebi's approval for its IPO. The offering includes an OFS by MakeMyTrip and its subsidiary, ibibo Group Holdings. The IPO aims to enhance brand visibility and strengthen financial position, with proceeds used for growth and acquisitions.

$MMYTMed

MakeMyTrip acquires Quick Ride's ride-pooling business

MakeMyTrip acquired a majority stake in Quick Ride's ride-pooling business, expanding into daily urban commuting. The Nasdaq-listed company will integrate Quick Ride into its ground transportation division, which includes redBus and Savaari. Quick Ride's promoters will continue managing the ride-pooling business, while its EV taxi operations remain separate. The acquisition aims to serve frequent, short-distance commuters, leveraging MakeMyTrip's existing travel experience.

$MMYTMedAI 8/10

SEBI Clears MakeMyTrip's India IPO

MakeMyTrip (India) Ltd received SEBI approval for its IPO, which will be an OFS by its Nasdaq-listed parent and subsidiary. The IPO could raise over $1B. MakeMyTrip India will remain a subsidiary post-listing. The company reported a Q2 FY27 profit of $1.8M and revenue of $235.2M.

$MMYTMed

MakeMyTrip India IPO Gets SEBI Approval for Listing

MakeMyTrip (India) Ltd received SEBI's approval for its IPO on November 6, 2026. The Nasdaq-listed parent company's subsidiary filed draft documents in July. The IPO will involve an offer for sale by MakeMyTrip and ibibo Group Holdings, with proceeds going to selling shareholders. MMT India will remain a subsidiary post-listing. IPO size, price band, and launch date are yet to be announced.

$MMYTMed

MakeMyTrip’s India arm gets Sebi nod to float IPO

MakeMyTrip's Indian subsidiary, MMT India, received Sebi approval for an IPO. The offering, expected to be a sale of equity shares by the parent and ibibo Group, aims to boost visibility, attract talent, and strengthen the parent's cash position. MMT India will remain a subsidiary post-IPO. Details on offer size, price, and timetable are yet to be disclosed.